Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Bladder Dysfunction Reports
Erschienen in: Current Bladder Dysfunction Reports 3/2013

01.09.2013 | Post-Prostatectomy and Acquired Voiding Dysfunction (C Comiter, Section Editor)

The Link Between Benign Prostatic Hyperplasia and Sexual Dysfunction

verfasst von: Donghua Xie, Bilal Chughtai, Dean S. Elterman, Stephan Seklehner, Richard Lee, Alexis E. Te, Steven A. Kaplan

Erschienen in: Current Bladder Dysfunction Reports | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Benign prostate hyperplasia (BPH) occurs in up to 50 % of men by age 50, and the incidence increases with age. The rate of erectile dysfunction (ED) in patients with BPH ranges from 30 to 70 %, but can be as high as 90.5 % in males aged over 50 years. BPH/lower urinary tract symptoms (LUTS) and sexual dysfunction (SD) can have a substantial negative impact on a man’s quality of life (QoL). Symptom severity and impact on QoL in each condition increase when LUTS and ED coexist. Age and erection change in patients with LUTS could also correlate with ejaculation dysfunction. However, urologists and primary care physicians appear to under-recognize SD in men with BPH/LUTS. We review the mechanisms of action, association, and effect of treatment between BPH and ED.
Literatur
1.
Kapoor A. Benign prostatic hyperplasia (BPH) management in the primary care setting. Can J Urol. 2012;19(5 Suppl 1):10–7.PubMed
2.
Song J, Shao Q, Tian Y, et al. Association between lower urinary tract symptoms and erectile dysfunction in males aged 50 years and above: results from a multicenter community-based cross-sectional survey (BPC-BPH). Zhonghua Yi Xue Za Zhi. 2011;91(38):2706–9.PubMed
3.
Hwa JS, Kam SC, Choi JH, et al. Impact of erectile function and age in men with lower urinary tract symptoms on ejaculatory dysfunction and premature ejaculation. Int J Impot Res. 2012;24(3):101–5.PubMedCrossRef
4.
Seftel AD, de la Rosette J, Birt J, et al. Coexisting lower urinary tract symptoms and erectile dysfunction: a systematic review of epidemiological data. Int J Clin Pract. 2013;67(1):32–45.PubMedCrossRef
5.
Mirone V, Sessa A, Giuliano F, et al. Current benign prostatic hyperplasia treatment: impact on sexual function and management of related sexual adverse events. Int J Clin Pract. 2011;65(9):1005–13.PubMedCrossRef
6.
Rouprêt M, Seisen T, De La Taille A, et al. Sexual dysfunctions linked with prostatic diseases. Prog Urol. 2012;22 Suppl 1:S14–20.PubMedCrossRef
7.
Nakamura M, Fujimura T, Nagata M, et al. Association between lower urinary tract symptoms and sexual dysfunction assessed using the core lower urinary tract symptom score and International Index of Erectile Function-5 questionnaires. Aging Male. 2012;15(2):111–4.PubMedCrossRef
8.
• Mazur DJ, Helfand BT, McVary KT. Influences of neuroregulatory factors on the development of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction in aging men. Urol Clin North Am. 2012;39(1):77–88. The article generated very vivid and clear diagrams to explain the pathophysiology linking aging with LUTS/BPH and ED based on evidence and novel speculation..PubMedCrossRef
9.
• Gacci M, Eardley I, Giuliano F, et al. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2011;60(4):809–25. This study did a very comprehensive and critical analysis of epidemiological data regarding the association of BPH/LUTS and sexual dysfunction..PubMedCrossRef
10.
Lee RK, Chung D, Chughtai B, et al. Central obesity as measured by waist circumference is predictive of severity of lower urinary tract symptoms. BJU Int. 2012;110(4):540–5.PubMedCrossRef
11.
Oudot A, Oger S, Behr-Roussel D, et al. A new experimental rat model of erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: the testosterone-supplemented spontaneously hypertensive rat. BJU Int. 2012;110(9):1352–8.PubMedCrossRef
12.
Vignozzi L, Morelli A, Sarchielli E, et al. Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit. J Endocrinol. 2012;212(1):71–84.PubMedCrossRef
13.
Vignozzi L, Cellai I, Santi R, et al. Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells. J Endocrinol. 2012;214(1):31–43.PubMedCrossRef
14.
Morelli A, Comeglio P, Filippi S, et al. Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: an experimental study in the rabbit. Prostate. 2012. doi:10.​1002/​pros.​22584.
15.
Bell JR, Laborde E. Update on the sexual impact of treatment for benign prostatic hyperplasia. Curr Urol Rep. 2012;13(6):433–40.PubMedCrossRef
16.
Zong HT, Peng XX, Yang CC, et al. The impact of transurethral procedures for benign prostate hyperplasia on male sexual function: a meta-analysis. J Androl. 2012;33(3):427–34.PubMedCrossRef
17.
Song SH, Son H, Kim KT, et al. Effect of tamsulosin on ejaculatory function in BPH/LUTS. Asian J Androl. 2011;13(6):846–50.PubMedCrossRef
18.
Hwang TI, Chu SH, Lin MS, et al. Impact of alfuzosin on sexual function in Taiwanese men with benign prostatic hyperplasia. Kaohsiung J Med Sci. 2012;28(8):429–34.PubMedCrossRef
19.
Faydaci G, Kuyumcuoglu U, Eryildirim B, et al. Effectiveness of doxazosin on erectile dysfunction in patients with lower urinary tract symptoms. Int Urol Nephrol. 2011;43(3):619–24.PubMedCrossRef
20.
Gur S, Kadowitz PJ, Hellstrom WJ. Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation. Expert Opin Drug Saf. 2013;12(1):81–90.PubMedCrossRef
21.
Corona G, Rastrelli G, Maseroli E, et al. Inhibitors of 5α-reductase-related side effects in patients seeking medical care for sexual dysfunction. J Endocrinol Invest. 2012;35(10):915–20.PubMed
22.
Kaplan SA, Chung DE, Lee RK, et al. A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride. Int J Clin Pract. 2012;66(11):1052–5.PubMedCrossRef
23.
Nickel JC, Gilling P, Tammela TL, et al. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU Int. 2011;108(3):388–94.PubMedCrossRef
24.
Pinsky MR, Gur S, Tracey AJ, et al. The effects of chronic 5-alpha-reductase inhibitor (dutasteride) treatment on rat erectile function. J Sex Med. 2011;8(11):3066–74.PubMedCrossRef
25.
Oztekin CV, Gur S, Abdulkadir NA, et al. Incomplete recovery of erectile function in rat after discontinuation of dual 5-alpha reductase inhibitor therapy. J Sex Med. 2012;9(7):1773–81.PubMedCrossRef
26.
Akman T, Binbay M, Tekinarslan E, et al. Effects of bipolar and monopolar transurethral resection of the prostate on urinary and erectile function: a prospective randomized comparative study. BJU Int. 2012. doi:10.​1111/​j.​1464-410X.​2012.​11266.​x.
27.
Kumar A, Vasudeva P, Kumar N, et al. Evaluation of the effect of photoselective vaporization of the prostate on sexual function in a prospective study: a single center experience of 150 patients. J Endourol 2012 [Epub ahead of print].
28.
Woo HH, Bolton DM, Laborde E, et al. Preservation of sexual function with the prostatic urethral lift: a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Sex Med. 2012;9(2):568–75.PubMedCrossRef
29.
30.
Lee M. Focus on phosphodiesterase inhibitors for the treatment of erectile dysfunction in older men. Clin Ther. 2011;33(11):1590–608.PubMedCrossRef
31.
Egerdie RB, Auerbach S, Roehrborn CG, et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. J Sex Med. 2012;9(1):271–81.PubMedCrossRef
32.
Lee JY, Park SY, Jeong TY, et al. Combined tadalafil and α-blocker therapy for benign prostatic hyperplasia in patients with erectile dysfunction: a multicenter, prospective study. J Androl. 2012;33(3):397–403.PubMedCrossRef
33.
Lee JY, Cho SY, Oh CY, et al. Efficacy and safety of combination therapy with mirodenafil and α1-blocker for benign prostatic hyperplasia-induced lower urinary tract symptoms accompanied by erectile dysfunction: a multicenter, open-label, prospective study. Int J Impot Res. 2011;23(6):249–56.PubMedCrossRef
34.
Gacci M, Corona G, Salvi M, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2012;61(5):994–1003.PubMedCrossRef
35.
Angulo J, Cuevas P, Fernández A, et al. Tadalafil enhances the inhibitory effects of tamsulosin on neurogenic contractions of human prostate and bladder neck. J Sex Med. 2012;9(9):2293–306.PubMedCrossRef
Metadaten
Titel
The Link Between Benign Prostatic Hyperplasia and Sexual Dysfunction
verfasst von
Donghua Xie
Bilal Chughtai
Dean S. Elterman
Stephan Seklehner
Richard Lee
Alexis E. Te
Steven A. Kaplan
Publikationsdatum
01.09.2013
Verlag
Springer US
Erschienen in
Current Bladder Dysfunction Reports / Ausgabe 3/2013
Print ISSN: 1931-7212
Elektronische ISSN: 1931-7220
DOI
https://doi.org/10.1007/s11884-013-0187-6

Weitere Artikel der Ausgabe 3/2013

Current Bladder Dysfunction Reports 3/2013 Zur Ausgabe

Inflammatory/Infectious Bladder Conditions (S Mourad, Section Editor)

Prostate Related Urinary Tract Infections

Inflammatory/Infectious Bladder Conditions (S Mourad, Section Editor)

Genital Filariasis Review

Inflammatory/Infectious Bladder Conditions (S Mourad, Section Editor)

Management of Recurrent Neurogenic Bladder Cystitis

Post-Prostatectomy and Acquired Voiding Dysfunction (C Comiter, Section Editor)

The Management of Acute Urinary Retention: Treating the Curse of the Aging Male

Post-Prostatectomy and Acquired Voiding Dysfunction (C Comiter, Section Editor)

Urinary Retention and Incontinence after Low-Dose-Rate Brachytherapy for Prostate Cancer

Inflammatory/Infectious Bladder Conditions (S Mourad, Section Editor)

Complications of Fungal Cystitis

Neu im Fachgebiet Urologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise